TMCI TREACE MEDICAL CONCEPTS, INC.

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business model: Development, marketing, and sales of bunion correction surgical systems and instruments in the U.S., primarily via direct sales force and distributors
• • New products emphasized: Minimally invasive osteotomy systems (Nanoplasty, Percuplasty), great toe fusion system, and next-gen Lapiplasty Lightning Instrumentation expected in 2026
• • Strategic shift: Addressing surgeon shift to minimally invasive bunion surgery with lower-priced new product lines; growing stocking distributor sales (from $0 to $13M in 2025)
• • Quantitative highlights: Active surgeons increased 6% to 3,337; direct sales force generated 80% of 2025 revenue; marketable securities $37.7M; legal expenses up $5.4M due to patent infringement lawsuits
• • Noteworthy fact: Filed multiple patent infringement lawsuits in 2024-2025 against major competitors Stryker and Zimmer Biomet over Lapiplasty 3D technology

Management Discussion & Analysis

• • Revenue $212.7M in 2025, up 1.6% YoY from $209.4M in 2024
• • Net loss increased to $59.0M in 2025 from $55.7M in 2024; operating margin negative approx. -25.5% in 2025 vs -26.6% in 2024 (loss from operations $54.2M vs $55.7M)
• • Best segment: not segmented; gross profit stable at $169.8M vs $168.3M; no segment-level details; worst metric: net loss deepening
• • Operating cash flow use $16.0M in 2025 vs $37.2M in 2024; investing cash inflow $13.3M in 2025 driven by sales/maturities of securities; financing cash inflow $2.1M in 2025 primarily from new term loan net proceeds ($59.3M) and repayments of prior loans ($56.3M)
• • Management expects existing cash, securities ($10.7M + $37.7M), and credit facilities sufficient for 12+ months; potential need to raise additional capital to support growth and operational needs; risks include market acceptance, competition, supply chain, economic factors, and litigation impacts

What are the latest TMCI SEC filings in 2026?

TREACE MEDICAL CONCEPTS, INC. (TMCI) has filed a 10-K annual report on February 27, 2026, a 10-Q quarterly report on May 8, 2026, an 8-K current report on August 7, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did TMCI file its most recent 10-K annual report?

TREACE MEDICAL CONCEPTS, INC. (TMCI) filed its most recent 10-K annual report on February 27, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view TMCI 10-Q quarterly reports?

TREACE MEDICAL CONCEPTS, INC. (TMCI)'s most recent 10-Q quarterly report was filed on May 8, 2026. SignalX displays every TMCI 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has TMCI filed recently?

TREACE MEDICAL CONCEPTS, INC. (TMCI)'s most recent 8-K was filed on August 7, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find TMCI insider trading activity (Form 4)?

SignalX aggregates every TMCI Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does TMCI file with the SEC?

TREACE MEDICAL CONCEPTS, INC. (TMCI) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new TMCI filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for TREACE MEDICAL CONCEPTS, INC. (TMCI).

What is TMCI's SEC CIK number?

TREACE MEDICAL CONCEPTS, INC. (TMCI)'s SEC CIK (Central Index Key) number is 1630627. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1630627 to look up all TMCI filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find TMCI return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from TREACE MEDICAL CONCEPTS, INC. (TMCI) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.